— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected.
— Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion.
— Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion.
— GILD shares have been trading sideways since the beginning of this year. The stock has so far declined 3% this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
FAST Stock: Fastenal’s long-term prospects intact. Should you invest now?
Production disruption and logistics issues continue to have a crippling effect on the industrial sector but the performance of companies, in general, has been mixed so far. Fastenal Company (NASDAQ:
Netflix (NFLX) adds 8.3 million new subscribers in Q4: earnings beat estimates
Netflix, Inc. (NASDAQ: NFLX) Thursday said it added 8.3 million paid members in the December quarter. Revenues increased and matched estimates, aided by the relaxation of COVID restrictions and resumption
SCHW Stock: Upbeat stock market, rate hikes to drive growth for Charles Schwab
Investment management firm Charles Schwab Corporation (NYSE: SCHW) has stayed largely unaffected by the coronavirus crisis, rather it managed to tap into new opportunities. The company owes its impressive financial
